FibroBiologics plans an at-the-market private placement of 4,081,633 shares (or pre-funded warrants) and series A and B warrants at $0.735 each, securing $3.0 million upfront and up to $9.0 million if all warrants are exercised. The financing is slated to close June 29, 2026, pending stockholder approval and closing conditions.
FibroBiologics has entered into definitive agreements to sell 4,081,633 shares of common stock or pre-funded warrants and accompanying series A and B warrants in an at-the-market private placement priced at $0.735 per share or warrant. The placement agent is H.C. Wainwright & Co., and the gross proceeds are expected to total $3.0 million upfront.
Each series A and short-term series B warrant carries an exercise price of $0.735 per share and becomes exercisable on or after the later of the stockholder approval date and the effective date of the resale registration statement. Series A warrants will expire five years after the later of those dates, while series B warrants will expire eighteen months after.
FibroBiologics intends to use net proceeds for working capital and general corporate purposes. The offering is expected to close on or about June 29, 2026, subject to customary closing conditions and stockholder approval of the issuance of shares upon exercise of the warrants.
